Finasteride CAS NO.98319-26-7

The non-androgenic amine is a basic medicine for treating prostatic hyperplasia and prostatitis in China, The level of the prostate specific antigen in the serum of the prostate is reduced, the prostate specific antigen in the serum is reduced, the volume of the prostate is increased, the flow rate of the urine is increased, and the symptoms of the patients can be reduced, and the purpose of treating the prostatic hyperplasia is achieved. The effect of the medicine is that the stimulation of the androgen to the prostate can be selectively blocked, and the sexual function of the male is rarely affected. The hyperplasia of the prostate is also called prostatic hypertrophy, which leads to the compression of the neck of the bladder and the posterior urethra, the obstruction of the urinary tract, and other symptoms and complications, which cause the patient to be deeply distressed and more than 50 years of age.

The pregnenolone is used as a raw material. And reacting with sodium methoxide to obtain 3-hydroxy-5-andromonoene-17-methyl-p-methyl-methyl-methyl (III). And then, in toluene and cyclohexanone, the isopropanol and the aluminum isopropoxide are refluxed. Filtering, washing, drying, and concentrating under reduced pressure. Adding petroleum ether, stirring at 5 & deg; C, filtering to obtain oxidized product (IV), and yield of 74.6%. The oxidation product and 95% ethanol and 10% potassium hydroxide solution were refluxed under nitrogen protection. After the ethanol was distilled off under reduced pressure, the Ph value was adjusted to about 3 with 6 mol of hydrochloric acid. Carrying out suction filtration, washing the filter cake with water to be neutral, and drying to obtain a hydrolysate (V) with a yield of 96.4%. Dissolving the hydrolysis product in tert-butanol, adding an aqueous solution of anhydrous sodium carbonate under stirring, dropwise adding an aqueous solution of sodium periodate and potassium permanganate under reflux, and performing reflux. Cooling and filtering. After the filtrate was distilled off under reduced pressure for most of the tert-butanol, the pH was adjusted to about 2 with 6 mol/ L hydrochloric acid in the ice bath. Extracting with ethyl acetate, washing with saturated sodium chloride, and drying. Evaporating to dryness under reduced pressure, and recrystallizing with ethyl acetate to obtain an open-loop product (VI) with a yield of 66%. And cooling the ice bath, introducing ammonia gas into the glycol, adding an open-loop product, and slowly raising to 180 DEG C for reaction. After cooling, add water, and adjust the pH to about 2 with 6 mol/ I. Filtering the solid, washing with water to neutral, and recrystallizing with dimethylamino amine to obtain the cyclization product (VII), and the yield is 62.1%. The cyclization product and dioxaliplatin, acetic acid and a small amount of perchloric acid were hydrogenated at 85.degree. C. and under normal pressure. After the catalyst was filtered off, the catalyst was concentrated to dryness under reduced pressure. The residue was recrystallized from dimethylamino amine to give a hydrogenation product (VIII) with a yield of 92.9%. The hydrogenated product is mixed with triphenylamine, toluene and 2,2 '-dicyandiamide (DPDS), stirred at room temperature, and separated by column chromatography to obtain a high-sulfur sulfide (sulfur) with a yield of 79.0%. The sulfide and the anhydrous tetrahydro-sulfur and tert-butylamine are stirred at room temperature overnight, and methylene chloride is added, Washing with 2 mol/ L hydrochloric acid and saturated sodium chloride, drying, and concentrating under reduced pressure. The residue is recrystallized from ethyl acetate to obtain a melamine product (X) with a yield of 77.1%. The crude product is recrystallized from ethyl acetate to obtain the white non-finasteride crystal with the yield of 52.3% and the melting point of 253-255 DEG C.